Tag Archives: PMTI

Rosen Law Firm Announces Investigation of Palomar Medical Technologies, Inc. in Connection with Its

By Business Wirevia The Motley Fool

Filed under:

Rosen Law Firm Announces Investigation of Palomar Medical Technologies, Inc. in Connection with Its Sale to Cynosure, Inc. – PMTI

NEW YORK–(BUSINESS WIRE)– The Rosen Law Firm, P.A. is investigating the Board of Directors of Palomar Medical Technologies, Inc. (“Palomar” or the “Company”) (NASDAQ GS: PMTI) for possible breaches of fiduciary duty and other violations of state law in connection with its sale of the Company to Cynosure, Inc. (NASDAQ GS: CYNO).

If you would like to join the action please email or call Phillip Kim or Kevin Chan, toll-free, at 866-767-3653; or email at pkim@rosenlegal.com or kchan@rosenlegal.com. There is no cost or obligation to you.

Under the terms of the transaction, shareholders will receive $13.65 for each share of Palomar stock they own – $6.825 per share in cash and $6.825 per share in Cynosure common stock. The investigation relates to whether the price of $13.65 per share in cash and Cynosure stock is fair to public shareholders and whether PMTI‘s Board breached its fiduciary duties in connection with the transaction.

If you own Palomar common stock and wish to obtain additional information, you may contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

The Rosen Law Firm P.A.
Phillip Kim, Esq.
Laurence Rosen, Esq.
275 Madison Avenue 34th Floor
New York, New York 10016
Tel: 212-686-1060
Weekends Tel: 917-562-8616
Toll Free: 1-866-767-3653
Fax: 212-202-3827
pkim@rosenlegal.com
lrosen@rosenlegal.com
www.rosenlegal.com

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:

The article Rosen Law Firm Announces Investigation of Palomar Medical Technologies, Inc. in Connection with Its Sale to Cynosure, Inc. – PMTI originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure …read more
Source: FULL ARTICLE at DailyFinance

Rigrodsky & Long, P.A. Announces Investigation Of Palomar Medical Technologies, Inc. Buyout

By Business Wirevia The Motley Fool

Filed under:

Rigrodsky & Long, P.A. Announces Investigation Of Palomar Medical Technologies, Inc. Buyout

WILMINGTON, Del.–(BUSINESS WIRE)– Rigrodsky & Long, P.A.:

  • Do you own shares of Palomar Medical Technologies, Inc. (NASDAQ GS: PMTI )?
  • Did you purchase any of your shares prior to March 18, 2013?
  • Do you think the proposed buyout price is too low?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Palomar Medical Technologies, Inc. (“Palomar” or the “Company”) (NASDAQ GS: PMTI) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Cynosure, Inc. (“Cynosure”) (NASDAQ GS: CYNO) in a transaction valued at approximately $294 million.

Click here to learn more: http://www.rigrodskylong.com/investigations/palomar-medical-technologies-inc-pmti.

Under the terms of the proposal, public shareholders of Palomar will receive $13.65 per share of Palomar common stock: $6.825 per share in cash and $6.825 per share in Cynosure common stock.

The investigation concerns whether Palomar’s board of directors failed to adequately shop the Company and obtain the best possible value for Palomar’s shareholders before entering into an agreement with Cynosure. According to Yahoo! Finance, at least one analyst has set a price target for Palomar stock at $14.50 per share.

If you own the common stock of Palomar and purchased your shares before March 18, 2013, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth Rigrodsky or Brian Long at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, Delaware 19803, by telephone at (302) 295-5310, or Peter Allocco at Rigrodsky & Long, P.A., …read more
Source: FULL ARTICLE at DailyFinance